# Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines

> **NCT02797028** · PHASE4 · UNKNOWN · sponsor: **Guangzhou General Hospital of Guangzhou Military Command** · enrollment: 320 (estimated)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **DIETARY_SUPPLEMENT:** Anthocyanidins capsule
- **DIETARY_SUPPLEMENT:** Placebo capsule
- **DRUG:** Allopurinol

## Key facts

- **NCT ID:** NCT02797028
- **Lead sponsor:** Guangzhou General Hospital of Guangzhou Military Command
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2016-10
- **Final completion:** 2017-12
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2016-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02797028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02797028, "Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02797028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*